shutterstock_2

University of Limerick’s Pharmaceutical Manufacturing Technology Centre to expand operations with €5m funding injection

pharmafile | September 3, 2019 | News story | Manufacturing and Production Ireland, UK, pharma 

The Pharmaceutical Manufacturing Technology Centre (PMTC) at the University of Limerick’s Bernal Institute in Ireland has secured €5 million ($5.5 million) in funding to launch a new phase of its operations. 

The Irish state-funded research centre is focused on the research and development of technological interventions for the pharma sector, connecting small and medium enterprises with the major multinational players to foster collaboration in research. Its membership comprises 38 firms, split between 60% SMEs and 40% multinationals.

Declan McGee from Enterprise Ireland explained the PMTC’s plans following the confirmation of this new funding injection: “In Phase 2, PMTC will have an enhanced emphasis on broadening its SME membership and will provide Enterprise Ireland clients with unrivalled interaction with biopharma multinationals. These SMEs will be well placed to grow through delivery of new technologies and solutions to MNCs in Ireland and beyond.”

For every €1 invested by the Irish State through to 2022, the economic value added by the PMTC will be €17.24, according to a recent evaluation, with improved efficiency and process innovation primarily driving this value growth.  

“The fact that the centre has been refunded really speaks to the successes of PMTC to date and importantly that there is an appetite for innovation from the broad industry base in Ireland with its globally unique eco-system in the biopharmaceutical sector,” commented recently appointed PMTC Director Sarah Hayes. “If you ask peers in pharma multinationals in Europe and the US, the research collaboration in Ireland is looked at with envy.”

“PMTC aims to grow its membership and work more closely with those existing members so that we understand their long term business needs and can quickly position ourselves to meet those opportunities,” she continued. “PMTC provides an introduction platform, giving the SMEs a place at the table so that they can directly engage in technical discussions with MNCs, which is a key enabler for those indigenous companies.”

Matt Fellows

Related Content

Astellas plans to invest over €330m in new facility in Ireland

Astellas Pharma has announced that it is preparing to submit a planning application to build …

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …

Latest content